Genoprotective effects of Amifostine against Mitoxantrone induced toxicity in HepG2 cells, detected via the Comet assay

Doxorubicin is a chemotherapy medication applied in the treatment of numerous cancers. Like other topoisomerase II inhibitors, doxorubicin has been shown genotoxic effects in both in vitro and in vivo models. Melatonin acts as a potent antioxidant. In additional, anti-inflammatory, anti-apoptotic, cytoprotective and genoprotective effects of melatonin have been reported in previous studies. The aim of present study was to determine protective role of melatonin nanoparticles against doxorubicin induced-genotoxicity. HepG2 cells were treated with various concentrations of doxorubicin, melatonin and nano melatonin in both pre- and cotreatment conditions and then analyzed via comet assay. Besides the intracellular reactive oxygen species and glutathione levels have been assessed. The results of current study show that doxorubicin induced a clear genotoxic effect in HepG2 cells. Melatonin and its nanoparticles decreased the genotoxic effects of doxorubicin significantly in both types of experiment states that exhibited by comet assay. Furthermore, both forms of melatonin decreased the intracellular reactive oxygen species generation and increased the intracellular glutathione contents in HepG2 cells. However, nano melatonin was more effective in attenuating of oxidative stress and DNA damage induced by doxorubicin.

Download Full-text

Assessment of the predictive capacity of the optimized in vitro comet assay using HepG2 cells

Mutation Research/Genetic Toxicology and Environmental Mutagenesis ◽

10.1016/j.mrgentox.2018.01.010 ◽

2018 ◽

Vol 827 ◽

pp. 59-67 ◽

Cited By ~ 8

Author(s):

Yoon-hee Hong ◽

Hye Lyun Jeon ◽

Kyung Yuk Ko ◽

Joohwan Kim ◽

Jung-Sun Yi ◽

...

Keyword(s):

Comet Assay ◽

Hepg2 Cells ◽

Predictive Capacity

Download Full-text

Genotoxicity and mutagenicity of inosine pranobex

Journal of Veterinary Research ◽

10.2478/jvetres-2018-0030 ◽

2018 ◽

Vol 62 (2) ◽

pp. 207-213 ◽

Cited By ~ 2

Author(s):

Sylwia Tobólska ◽

Sylwia Terpiłowska ◽

Jerzy Jaroszewski ◽

Andrzej Krzysztof Siwicki

Keyword(s):

Comet Assay ◽

Hepg2 Cells ◽

Ames Test ◽

Viral Infections ◽

Antiviral Drug ◽

Micronucleus Assay ◽

Inosine Pranobex ◽

Hepg2 Cell Lines ◽

Mutation Assay ◽

Related Increase

AbstractIntroductionInosine pranobex (Methisoprinol, ISO, Isoprinosine) is an immuno-modulatory antiviral drug that has been licensed since 1971 in several countries worldwide. In humans, the drug is approved for the treatment of viral infections, and it might also have therapeutic use in animals. The aims of the presented work were to investigate the genotoxicity of inosine pranobex on BALB/3T3 clone A1 and HepG2 cell lines and to elucidate its mutagenicity using the Ames test.Material and MethodsThe BALB/3T3 clone A1 and HepG2 cells were incubated with inosine pranobex at concentrations from 0.1 to 1,000 μg/mL. The genotoxicity was determined by comet and micronucleus assays, and the mutagenicity was determined by Ames assay.ResultsInosine pranobex did not induce a significant dose-related increase in the number of comets or micronuclei in BALB/3T3 clone A1 and HepG2 cells. Moreover, based on the results of the Ames test, it was concluded that inosine pranobex is not mutagenic in theSalmonella typhimuriumreverse mutation assay.ConclusionBased on the results of a comet assay, micronucleus assay, and Ames test, it was concluded that inosine pranobex is neither genotoxic nor mutagenic.

Download Full-text